Oskouei, S. T. and A. R. Kusmierczyk (2021) Biosimilar uptake: the importance of healthcare provider education. Pharmaceut. Med. 35: 215–224.
PubMed PubMed Central Google Scholar
Bhunia, B., B. Basak, T. Mandal, P. Bhattacharya, and A. Dey (2013) Effect of pH and temperature on stability and kinetics of novel extracellular serine alkaline protease (70kDa). Int. J. Biol. Macromol. 54: 1–8.
Joshi, S., S. Kumari, and A. S. Rathore (2021) Identification and characterization of carbonylation sites in trastuzumab biosimilars. Int. J. Biol. Macromol. 169: 95–102.
Reslan, M., V. Sifniotis, E. Cruz, Z. Sumer-Bayraktar, S. Cordwell, and V. Kayser (2020) Enhancing the stability of adalimumab by engineering additional glycosylation motifs. Int. J. Biol. Macromol. 158: 189–196.
Beck, A., T. Wurch, C. Bailly, and N. Corvaia (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10: 345–352.
Perobelli, R. F., B. Xavier, A. R. da Silveira, G. L. Remuzzi, L. G. J. Motta, and S. L. Dalmora (2018) Quantitation of the monoclonal antibody Denosumab by bioassay and validated LC methods. Int. J. Biol. Macromol. 119: 96–104.
McAtee, C. P. and J. Hornbuckle (2012) Isolation of monoclonal antibody charge variants by displacement chromatography. Curr. Protoc. Protein Sci. 69: 8.10.1–8.10.13.
Kadkhoda, J., M. Akrami-Hasan-Kohal, M. R. Tohidkia, S. Khaledi, S. Davaran, and A. Aghanejad (2021) Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends. Int. J. Biol. Macromol. 185: 664–678.
Lu, R.-M., Y.-C. Hwang, I.-J. Liu, C.-C. Lee, H.-Z. Tsai, H.-J. Li, and H.-C. Wu (2020) Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27: 1.
CAS PubMed PubMed Central Google Scholar
Berkowitz, S. A., J. R. Engen, J. R. Mazzeo, and G. B. Jones (2012) Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11: 527–540.
CAS PubMed PubMed Central Google Scholar
Vlasak, J., M. C. Bussat, S. Wang, E. Wagner-Rousset, M. Schaefer, C. Klinguer-Hamour, M. Kirchmeier, N. Corvaïa, R. Ionescu, and A. Beck (2009) Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal. Biochem. 392: 145–154.
Khawli, L. A., S. Goswami, R. Hutchinson, Z. W. Kwong, J. Yang, X. Wang, Z. Yao, A. Sreedhara, T. Cano, D. Tesar, I. Nijem, D. E. Allison, P. Y. Wong, Y.-H. Kao, C. Quan, A. Joshi, R. J. Harris, and P. Motchnik (2010) Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs. 2: 613–624.
PubMed PubMed Central Google Scholar
Shen, Z., Y. Wang, H. Xu, Q. Zhang, C. Sha, B. Sun, and Q. Li (2021) Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate. Int. J. Biol. Macromol. 180: 494–509.
Simoens, S. and A. G. Vulto (2021) A health economic guide to market access of biosimilars. Expert Opin. Biol. Ther. 21: 9–17.
Agbogbo, F. K., D. M. Ecker, A. Farrand, K. Han, A. Khoury, A. Martin, J. McCool, U. Rasche, T. D. Rau, D. Schmidt, M. Sha, and N. Treuheit (2019) Current perspectives on biosimilars. J. Ind. Microbiol. Biotechnol. 46: 1297–1311.
Niazi, S. K. (2019) Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. 3rd ed., pp. 95–100. CRC Press.
Vanam, R. P., M. A. Schneider, and M. S. Marlow (2015) Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity. mAbs. 7: 1118–1127.
CAS PubMed PubMed Central Google Scholar
Neill, A., C. Nowak, R. Patel, G. Ponniah, N. Gonzalez, D. Miano, and H. Liu (2015) Characterization of recombinant monoclonal antibody charge variants using OFFGEL fractionation, weak anion exchange chromatography, and mass spectrometry. Anal. Chem. 87: 6204–6211.
Zheng, J. Y. and L. J. Janis (2006) Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int. J. Pharm. 308: 46–51.
Brown, K. A., S. Rajendran, J. Dowd, and D. J. Wilson (2019) Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach. Drug Test Anal. 11: 1207–1217.
Majumder, S. K., M. K. Sharma, and T. K. Gupta (2011) Liquid formulation of follicle stimulating hormone. European Patent EP2533800B1.
Majumder, S. K., and T. K. Gupta (2014) Process for the purification of fc fusion. WIPO (PCT) WO2014102814A1.
Du, Y., A. Walsh, R. Ehrick, W. Xu, K. May, and H. Liu (2012) Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. mAbs. 4: 578–585.
PubMed PubMed Central Google Scholar
Cramer, S. M. and M. A. Holstein (2011) Downstream bioprocessing: recent advances and future promise. Curr. Opin. Chem. Eng. 1: 27–37.
Chon, J. H. and G. Zarbis-Papastoitsis (2011) Advances in the production and downstream processing of antibodies. New Biotechnol. 28: 458–463.
Shukla, A. A. and J. Thömmes (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 28: 253–261.
Rathore, A. S., R. Bhambure, and V. Ghare (2010) Process analytical technology (PAT) for biopharmaceutical products. Anal. Bioanal. Chem. 398: 137–154.
Li, F., Y. Hashimura, R. Pendleton, J. Harms, E. Collins, and B. Lee (2006) A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol. Prog. 22: 696–703.
Yoo, E. M., K. R. Chintalacharuvu, M. L. Penichet, and S. L. Morrison (2002) Myeloma expression systems. J. Immunol. Methods 261: 1–20.
Costa, A. R., M. E. Rodrigues, M. Henriques, J. Azeredo, and R. Oliveira (2010) Guidelines to cell engineering for monoclonal antibody production. Eur. J. Pharm. Biopharm. 74: 127–138.
Jordan, M., D. Voisard, A. Berthoud, L. Tercier, B. Kleuser, G. Baer, and H. Broly (2013) Cell culture medium improvement by rigorous shuffling of components using media blending. Cytotechnology 65: 31–40.
Li, F., N. Vijayasankaran, A. (Yijuan) Shen, R. Kiss, and A. Amanullah (2010) Cell culture processes for monoclonal antibody production. mAbs. 2: 466–479.
PubMed PubMed Central Google Scholar
Liu, H. F., J. Ma, C. Winter, and R. Bayer (2010) Recovery and purification process development for monoclonal antibody production. mAbs. 2: 480–499.
PubMed PubMed Central Google Scholar
Fahrner, R. L., H. L. Knudsen, C. D. Basey, W. Galan, D. Feuerhelm, M. Vanderlaan, and G. S. Blank (2001) Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 18: 301–327.
Manning, M. C., D. K. Chou, B. M. Murphy, R. W. Payne, and D. S. Katayama (2010) Stability of protein pharmaceuticals: an update. Pharm. Res. 27: 544–575.
Talebi, M., A. Nordborg, A. Gaspar, N. A. Lacher, Q. Wang, X. Z. He, P. R. Haddad, and E. F. Hilder (2013) Charge heterogeneity profiling of monoclonal antibodies using low ionic strength ion-exchange chromatography and well-controlled pH gradients on monolithic columns. J. Chromatogr. A 1317: 148–154.
Wagner-Rousset, E., S. Fekete, L. Morel-Chevillet, O. Colas, N. Corvaïa, S. Cianférani, D. Guillarme, and A. Beck (2017) Development of a fast workflow to screen the charge variants of therapeutic antibodies. J. Chromatogr. A 1498: 147–154.
Liu H., G. Gaza-Bulseco, D. Faldu, C. Chumsae, and J. Sun (2008) Heterogeneity of monoclonal antibodies. J. Pharm. Sci. 97: 2426–2447.
Dick Jr, L. W., D. Qiu, D. Mahon, M. Adamo, and K.-C. Cheng (2008) C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol. Bioeng. 100: 1132–1143.
Yüce, M., F. Sert, M. Torabfam, A. Parlar, B. Gürel, N. Çakır, D. E. Dağlıkoca, M. A. Khan, and Y. Çapan (2021) Fractionated charge variants of biosimilars: a review of separation methods, structural and functional analysis. Anal. Chim. Acta 1152: 238189.
Perkins, M., R. Theiler, S. Lunte, and M. Jeschke (2000) Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm. Res. 17: 1110–1117.
Yan, B., S. Steen, D. Hambly, J. Valliere-Douglass, T. V. Bos, S. Smallwood, Z. Yates, T. Arroll, Y. Han, H. Gadgil, R. F. Latypov, A. Wallace, A. Lim, G. R. Kleemann, W. Wang, and A. Balland (2009) Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J. Pharm. Sci. 98: 3509–3521.
Singh, S. K., G. Narula, and A. S. Rathore (2016) Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes? Electrophoresis 37: 2338–2346.
Saxena, A., M. Kumar, B. P. Tripathi, and V. K. Shahi (2010) Organic-inorganic hybrid charged membranes for proteins separation: isoelectric separation of proteins under coupled driving forces. Sep. Purif. Technol. 70: 280–290.
Fekete, S., A. Beck, J. Fekete, and D. Guillarme (2015) Method development for the separation of monoclonal antibody charge variants in cation exchange chromatography Part II: pH gradient approach. J. Pharm. Biomed. Anal. 102: 282–289.
Fekete, S., A. Beck, J.-L. Veuthey, and D. Guillarme (2015) Ion-exchange chromatography for the characterization of biopharmaceuticals. J. Pharm. Biomed. Anal.
留言 (0)